The efficacy of buspirone combined with paroxetine in the treatment of depression
Tao Xi
Abstract
Tao Xi
Abstract
Objective To explore the clinical efficacy and safety ofbuspirone combined with paroxetine in the treatment of depression.Methods 76 patients diagnosed as depression according to the diagnostic criteria on the CCMD-3 were randomly divided into study group and control group.Both groups received paroxetine,while the study group received additional buspirone.Hamilton Depression Rating Scale (HAMD) and Treatment Emergent Symptom Scale (TESS) were used for evaluation before treatment and 1,2,4,and 6 weeks after treatment.Results The effectiveness rate was significantly higher in the study group than in the control group (97.3% vs.89.5%,P<0.05).The scores on the HAMD was significantly lower in the study group than in the control group 2,4,and 6 weeks after treatment (P<0.05).There was no significant difference between the two groups in the scores on the TESS (P>0.05).Conclusions buspirone can enhance the clinical efficacy of paroxetine in the treatment of depression while does not increase the incidence of adverse reactions.It is worth popularizing clinically. Key words: Buspirone; Paroxetine; Depression
A significance statement is not available in the OpenAlex record.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Objective To explore the clinical efficacy and safety ofbuspirone combined with paroxetine in the treatment of depression.Methods 76 patients diagnosed as depression according to the diagnostic criteria on the CCMD-3 were randomly divided into study group and control group.Both groups received paroxetine,while the study group received additional buspirone.Hamilton Depression Rating Scale (HAMD) and Treatment Emergent Symptom Scale (TESS) were used for evaluation before treatment and 1,2,4,and 6 weeks after treatment.Results The effectiveness rate was significantly higher in the study group than in the control group (97.3% vs.89.5%,P<0.05).The scores on the HAMD was significantly lower in the study group than in the control group 2,4,and 6 weeks after treatment (P<0.05).There was no significant difference between the two groups in the scores on the TESS (P>0.05).Conclusions buspirone can enhance the clinical efficacy of paroxetine in the treatment of depression while does not increase the incidence of adverse reactions.It is worth popularizing clinically. Key words: Buspirone; Paroxetine; Depression
Key concepts: Hamd, Paroxetine, Buspirone, Depression (economics), Clinical efficacy, Hamilton depression scale, Rating scale, Medicine